End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
730 MXN | +5.04% | +5.72% | -15.85% |
03:31pm | Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients | MT |
02:38pm | Bristol Myers: positive results in liver cancer | CF |
Sales 2024 * | 46.09B 817B | Sales 2025 * | 46.06B 816B | Capitalization | 84.67B 1,501B |
---|---|---|---|---|---|
Net income 2024 * | -5.41B -95.98B | Net income 2025 * | 10.22B 181B | EV / Sales 2024 * | 2.68 x |
Net Debt 2024 * | 39.03B 692B | Net Debt 2025 * | 31.68B 562B | EV / Sales 2025 * | 2.53 x |
P/E ratio 2024 * |
-15.9
x | P/E ratio 2025 * |
7.9
x | Employees | 34,100 |
Yield 2024 * |
5.76% | Yield 2025 * |
6.05% | Free-Float | 69.27% |
Latest transcript on Bristol-Myers Squibb Company
1 day | +5.04% | ||
1 week | +5.72% | ||
Current month | +5.04% | ||
1 month | -1.96% | ||
3 months | -15.12% | ||
6 months | -14.32% | ||
Current year | -15.85% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 730 | +5.04% | 24 |
24-05-31 | 695 | +1.39% | 3,960 |
24-05-30 | 685.5 | -0.22% | 1,829 |
24-05-29 | 687 | +0.61% | 892 |
End-of-day quote Mexican S.E., June 02, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.27% | 748B | |
+33.99% | 598B | |
-5.93% | 356B | |
+18.36% | 325B | |
+4.79% | 283B | |
+17.40% | 245B | |
+9.07% | 211B | |
-4.34% | 209B | |
+2.69% | 166B |
- Stock Market
- Equities
- BMY Stock
- BMY * Stock